Document is current
Any future updates will be listed below
-
Authors
Leonard, Rebecca A. https://orcid.org/0000-0002-3404-0399
Burke, Kaitlyn N.
Spreng, Rachel L. https://orcid.org/0000-0003-1254-0760
Macintyre, Andrew N.
Tam, Ying https://orcid.org/0000-0002-4083-5251
Alameh, Mohamad-Gabriel https://orcid.org/0000-0002-5672-6930
Weissman, Drew
Heaton, Nicholas S. https://orcid.org/0000-0002-5307-3428
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (75N93019C00050)
- License Information
-
More Information
Article History
Received: 24 May 2024
Accepted: 24 September 2024
First Online: 8 October 2024
Competing interests
: Duke University has filed for protection of intellectual property related to the vaccine approach described in this manuscript on behalf of N.S.H. Y.T. is an officer with Acuitas Therapeutics, a company dedicated to the development of lipid nanoparticulate nucleic acid delivery systems for therapeutic and other applications. Y.T. is named on patents describing uses of modified mRNA LNPs. D.W. is a coinventor on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins or vaccines. The remaining authors declare no competing interests.
